In terms of targeting HH signaling, although the current clinical activities are towards broad therapeutic effects in TNBC or HER-2 positive breast cancer—two BCSC-enriched breast cancer types—it is also promising to effectively eliminate BCSCs in metastatic and relapsed breast cancer. Here, ERBB2 is linked to breast cancer.